← Product Code [GQX](/submissions/MI/subpart-d%E2%80%94serological-reagents/GQX) · K951799 # VARICELLA-ZOSTER VIRUS DIRECT IMMUNOFLUORESCENCE ASSAY (K951799) _Light Diagnostics · GQX · Mar 20, 1996 · Microbiology · SESE_ **Canonical URL:** https://fda.innolitics.com/submissions/MI/subpart-d%E2%80%94serological-reagents/GQX/K951799 ## Device Facts - **Applicant:** Light Diagnostics - **Product Code:** [GQX](/submissions/MI/subpart-d%E2%80%94serological-reagents/GQX.md) - **Decision Date:** Mar 20, 1996 - **Decision:** SESE - **Submission Type:** Traditional - **Regulation:** 21 CFR 866.3900 - **Device Class:** Class 2 - **Review Panel:** Microbiology ## Indications for Use Light Diagnostics Varicella-zoster virus Direct Immunofluorescence Assay is intended for in vitro diagnostic use in the qualitative detection of VZV from vesicular smears and in cell culture viral isolation and confirmation. ## Device Story Direct immunofluorescence assay (DFA) for VZV identification; utilizes mouse monoclonal antibodies conjugated to fluorescein isothiocyanate (FITC). Input: vesicular smear specimens or tissue culture cells. Principle: monoclonal antibodies bind to VZV glycoprotein gp I or immediate early antigen; antigen-antibody complex visualized via fluorescence microscopy. Used in clinical laboratories by trained personnel. Output: qualitative detection of VZV antigen. Benefits: rapid, specific identification of VZV compared to traditional culture methods; aids clinical diagnosis of varicella or zoster infections. ## Clinical Evidence Clinical evaluation compared subject device to Merifluor VZV using 205 specimens. Results showed sensitivity (95% CI) of 91.3% to 100% and specificity (95% CI) of 96.2% to 100%. Nonclinical evaluation confirmed reactivity with reference strains and clinical isolates, with no cross-reactivity to other viral pathogens. ## Technological Characteristics Direct immunofluorescence assay (DFA). Reagents: mouse monoclonal antibodies specific for VZV glycoprotein gp I or immediate early antigen, conjugated to fluorescein isothiocyanate (FITC). Detection method: fluorescence microscopy. No electronic or software components. ## Regulatory Identification Varicella-zoster virus serological reagents are devices that consist of antigens and antisera used in serological tests to identify antibodies to varicella-zoster in serum. The identification aids in the diagnosis of diseases caused by varicella-zoster viruses and provides epidemiological information on these diseases. Varicella (chicken pox) is a mild, highly infectious disease, chiefly of children. Zoster (shingles) is the recurrent form of the disease, occurring in adults who were previously infected with varicella-zoster viruses. Zoster is the response (characterized by a rash) of the partially immune host to a reactivation of varicella viruses present in latent form in the patient's body. ## Predicate Devices - Meridian Diagnostics, Inc. Merifluor VZV ## Submission Summary (Full Text) > This content was OCRed from public FDA records by [Innolitics](https://innolitics.com). If you use, quote, summarize, crawl, or train on this content, cite Innolitics at https://innolitics.com. > > Innolitics is a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices, including [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/). {0} Kc7799 # 510(k) SUMMARY MAR 20 1996 1. 510(k) **Light Diagnostics** 28835 Single Oak Drive Temecula, California 92590 Contact Person: Dale Dembrow (909) 676-8080 Extension 230 2. Device: **Light Diagnostics** **Varicella-zoster Virus Direct Immunofluorescence Assay** A direct immunofluorescence assay for the identification of Varicella-zoster virus 3. Substantial Equivalence to: **Meridian Diagnostics, Inc.** **Merifluor VZV** Varicella-zoster virus direct fluorescence antibody stain for VZV identification. 4. Device Description: **Light Diagnostics** Varicella-zoster virus direct Immunofluorescence Assay (VZV DFA) uses the standard laboratory direct immunofluorescence technique for the culture confirmation and direct specimen detection of Varicella-zoster virus. The DFA is based on the principle of antigen identification using a detector monoclonal antibody conjugated to fluorescein isothiocyanate. The substrate consists of a slide prepared from a direct specimen vesicular smear or the tissue cultured cells from a clinical specimen inoculum. Anti VZV FITC labeled antibody is applied to the substrate. The antibody will bind to specific antigen, if present, in the substrate. The fluorescein conjugated monoclonal antibody allows for visualization of the antigen / antibody complex by fluorescence microscopy. A blend of mouse monoclonal antibodies are used as detector antibodies in **Light Diagnostics** Varicella-zoster virus direct Immunofluorescence Assay. The monoclonal antibodies are specific for the glycoprotein gp I or the immediate early antigen of VZV. The use of monoclonal antibodies ensures increased specificity and reduced non-specific interference. {1} # 510(k) SUMMARY 5. Intended Use: *Light Diagnostics* Varicella-zoster virus Direct Immunofluorescence Assay is intended for in vitro diagnostic use in the qualitative detection of VZV from vesicular smears and in cell culture viral isolation and confirmation. 6. Technological Characteristics Comparison of *Light Diagnostics* Varicella-zoster virus Direct Immunofluorescence Assay and the Merifluor VZV kit: a. Principle: Both kits use standard immunofluorescence assay technique using substrate slides prepared from vesicular smears or the cells from tissue culture isolation. b. Materials: Both kits incorporate monoclonal antibodies specific for VZV as the detector antibodies. ## Performance Data for Light Diagnostics Varicella-zoster virus Direct Immunofluorescence Assay Kit 1. Nonclinical evaluation: The conjugated monoclonal antibodies used in the kit were characterized for their ability to detect Varicella-zoster virus. The anti VZV antibodies reacted concordantly when tested with reference virus strains and clinical isolates. The conjugated monoclonal antibodies were evaluated for cross reactivity to a variety of viral pathogens and host cell controls. No discordant results were obtained. 2. Clinical Evaluation: *Light Diagnostics* Varicella-zoster virus Direct Immunofluorescence Assay was compared in clinical evaluation to the Meridian Diagnostics, Inc. Merifluor kit for direct specimen detection and cell culture isolation / confirmation. Two hundred and five specimens were evaluated with results for 95% confidence interval sensitivity of 91.3% to 100% and specificity of 96.2% to 100%. {2} # 510(k) SUMMARY 3. Conclusions Drawn from Evaluations: *Light Diagnostics* Varicella-zoster virus Direct Immunofluorescence Assay Kit uses the standard laboratory DFA in the culture confirmation and direct detection of Varicella-zoster virus. The monoclonal antibodies used in the kit have been characterized to ensure maximum specificity and reliability. In clinical evaluations, the kit performed consistent with results obtained using the Meridian Diagnostics, Inc. Merifluor VZV in vitro diagnostic kit. The characterization and clinical evaluation of *Light Diagnostics* Varicella-zoster Direct Immunofluorescence Assay* verifies its safety and effectiveness when used as intended. --- **Source:** [https://fda.innolitics.com/submissions/MI/subpart-d%E2%80%94serological-reagents/GQX/K951799](https://fda.innolitics.com/submissions/MI/subpart-d%E2%80%94serological-reagents/GQX/K951799) **Published by [Innolitics](https://innolitics.com)** — a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices. If you're preparing [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/), [get in touch](https://innolitics.com/contact). **Cite:** Innolitics at https://innolitics.com